Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Longeveron® to Attend BIO International Convention 2024
08:05am, Tuesday, 28'th May 2024
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic agin
Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript
11:08pm, Friday, 17'th May 2024
Longeveron Inc. (NASDAQ:LGVN ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - Chief Medical O
Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript
11:08pm, Friday, 17'th May 2024
Longeveron Inc. (NASDAQ:LGVN ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - Chief Medical O
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
04:05pm, Tuesday, 14'th May 2024
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
04:05pm, Friday, 10'th May 2024
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar, former head of R&D at Ring Therapeutics,
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
08:03am, Thursday, 02'nd May 2024
MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024
Longeveron to Present at the Planet MicroCap Showcase
04:05pm, Thursday, 25'th Apr 2024
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Plan
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
04:05pm, Thursday, 18'th Apr 2024
MIAMI, April 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threate
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
08:00am, Wednesday, 17'th Apr 2024
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer's Disease has been accepted for two presentations at AAIC.
Why Is Longeveron (LGVN) Stock Up 48% Today?
08:24am, Monday, 15'th Apr 2024
Longeveron (NASDAQ: LGVN ) stock is up on Monday alongside a couple of pieces of news from the clinical-stage biotechnology company. First off, investors will note that there's insider buying they ne
Longeveron Announces Closing of $5.2 Million Public Offering
05:17pm, Thursday, 11'th Apr 2024
MIAMI, April 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for life-threate
Future Predictions for Trading Penny Stocks, 3 Changes
06:22am, Tuesday, 09'th Apr 2024
The dynamic landscape of investing in penny stocks is poised for notable shifts in the coming year, presenting both seasoned and novice traders with a plethora of opportunities. Key factors contributi
Longeveron Announces Pricing of $5.25 Million Public Offering
02:15pm, Monday, 08'th Apr 2024
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08:30am, Monday, 08'th Apr 2024
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company's CEO, Wa'el Hashad
